Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Thromb Thrombolysis ; 52(4): 1094-1100, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1525569

ABSTRACT

Impact of pandemic on the incidence of venous thromboembolism (VTE) in non-COVID-19 patients is undetermined. Thus, a nationwide multicenter retrospective survey was conducted to evaluate the disease burden in non-COVID-19 population. This multi-center survey involved 94 hospitals from 24 provinces in the mainland of China, and collected data on non-COVID-19 patients admitted to the radiology departments due to VTE between January 24 and April 16, 2020. Baseline characteristics, VTE risk factors, clinical manifestations and the treatments were compared with those in the same period of 2019. 3,358 patients with VTE from 74 hospitals were included in this study (1,458 in 2020, 1,900 in 2019). Most aged ≥ 50 years (80.6% in the pandemic, 81.2% in 2019). The number of patients aged 30-39 years increased from 3.9% in 2019 period to 5.8% in the pandemic (p = 0.009). Among the VTE risk factors, the rate of decreased activity increased significantly in the pandemic, and was much higher than that in 2019 (30.7% vs 22.6%, p < 0.0001). Under the risk of decreased activity, patients with comorbidities chronic diseases, especially diabetes, showed significantly a higher incidence of VTE (30.4% vs 22.0%, p < 0.0001). In the pandemic period, fewer patients were treated with anticoagulation alone (33.5% vs 36.7%, p = 0.05), and more underwent inferior vena cava filter (IVCF) implantation, compared with those in 2019 (66.5% vs 63.2%, p = 0.046). The pandemic increased the VTE risk of decreased activity among the non-COVID-19 population. Patients with comorbidities, especially diabetes, have a significant higher risk of VTE during the pandemic.


Subject(s)
Pandemics , Vena Cava Filters , Venous Thromboembolism , Adult , COVID-19 , Humans , Middle Aged , Retrospective Studies , Risk Factors , Venous Thromboembolism/epidemiology
2.
Journal of Southwest Minzu University Natural Science Edition ; 46(4):354-369, 2020.
Article in Chinese | GIM | ID: covidwho-1372327

ABSTRACT

This study was to combine network pharmacology with molecular docking technology, and the purpose was to explore the potential pharmacodynamic substances of Ma-Xing-Shi-Gan decoction in the treatment of COVID-19 and to predict the mechanism. Firstly, the main active components and targets were screened using TCMSP database, and Cytoscape software was used to construct the "active component-target" network. The Uniprot database and Genecards database were used to obtain the target protein genes and disease targets respectively, and the common targets were uploaded to STRING database to construct the core network of protein interaction to screen out the core targets. GO functional enrichment analysis and KEGG pathway analysis were performed using DAVID database. Finally, molecular docking software was used to dock and screen the key active components and therapeutic targets. The results showed that Ma-Xing-Shi-Gan decoction contained multiple active ingredients acting on multiple targets, and played a role in the treatment of COVID-19 through multiple pathways such as inflammatory pathways, suppression of cytokine storms, and immune regulation.

3.
Journal of Southwest Minzu University Natural Science Edition ; 46(2):141-160, 2020.
Article in Chinese | GIM | ID: covidwho-1350786

ABSTRACT

The novel coronavirus(2019-nCoV) induced acute pneumonia is classified as "wet poison epidemic" in traditional Chinese medicine(TCM). With the development of the epidemic situation, several preventive and therapeutic procedures of TCM against the novel coronavirus-infected pneumonia have been issued by the National Health Commission and the State Administration of TCM according to the local climate characteristics, human population quality, and patient clinical performance. Recently, the epidemic situation in China has been gradually under effective control, and TCM has shown clear efficacy in the prevention and treatment of COVID-19. The authors systematically summarized the prevention and treatment programs of TCM for 2019-nCoV pneumonia published in 23 provinces and municipalities of China, and then analyzed the medication rules, explored the therapeutic advantages and characteristic functions of TCM in the prevention and treatment of 2019-nCoV pneumonia, and provided some useful suggestions for the diagnosis and treatment of 2019-nCoV pneumonia.

4.
Medicine (Baltimore) ; 100(20): e25916, 2021 May 21.
Article in English | MEDLINE | ID: covidwho-1236279

ABSTRACT

ABSTRACT: The outbreak and widely spread of coronavirus disease 2019 (COVID-19) has become a global public health concern. COVID-19 has caused an unprecedented and profound impact on the whole world, and the prevention and control of COVID-19 is a global public health challenge remains to be solved. The retrospective analysis of the large scale tests of SARS-CoV-2 RNA may indicate some important information of this pandemic. We selected 12400 SARS-CoV-2 tests detected in Wuhan in the first semester of 2020 and made a systematic analysis of them, in order to find some beneficial clue for the consistent prevention and control of COVID-19.SARS-CoV-2 RNA was detected in suspected COVID-19 patients with real-time fluorescence quantitative PCR (RT-qPCR). The patients' features including gender, age, type of specimen, source of patients, and the dynamic changes of the clinical symptoms were recorded and statistically analyzed. Quantitative and qualitive statistical analysis were carried out after laboratory detection.The positive rate of SARS-CoV-2 was 33.02% in 12,400 suspected patients' specimens in Wuhan at the first months of COVID-19 epidemics. SARS-CoV-2 RT-qPCR test of nasopharyngeal swabs might produce 4.79% (594/12400) presumptive results. The positive rate of SARS-CoV-2 RNA was significantly different between gender, age, type of specimen, source of patients, respectively (P < .05). The median window period from the occurrence of clinical symptom or close contact with COVID-19 patient to the first detection of positive PCR was 2 days (interquartile range, 1-4 days). The median interval time from the first SARS-CoV-2 positive to the turning negative was 14 days (interquartile range, 8-19.25 days).This study reveals the comprehensive characteristics of the SARS-CoV-2 RNA detection from multiple perspectives, and it provides important clues and may also supply useful suggestions for future work of the prevention and treatment of COVID-19.


Subject(s)
COVID-19 Nucleic Acid Testing/statistics & numerical data , COVID-19/diagnosis , RNA, Viral/analysis , Real-Time Polymerase Chain Reaction/statistics & numerical data , SARS-CoV-2/genetics , Adult , Aged , COVID-19/epidemiology , COVID-19 Nucleic Acid Testing/methods , China/epidemiology , Female , Humans , Male , Middle Aged , Nasopharynx/virology , Real-Time Polymerase Chain Reaction/methods , Retrospective Studies
5.
J Thromb Thrombolysis ; 52(4): 1094-1100, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1227891

ABSTRACT

Impact of pandemic on the incidence of venous thromboembolism (VTE) in non-COVID-19 patients is undetermined. Thus, a nationwide multicenter retrospective survey was conducted to evaluate the disease burden in non-COVID-19 population. This multi-center survey involved 94 hospitals from 24 provinces in the mainland of China, and collected data on non-COVID-19 patients admitted to the radiology departments due to VTE between January 24 and April 16, 2020. Baseline characteristics, VTE risk factors, clinical manifestations and the treatments were compared with those in the same period of 2019. 3,358 patients with VTE from 74 hospitals were included in this study (1,458 in 2020, 1,900 in 2019). Most aged ≥ 50 years (80.6% in the pandemic, 81.2% in 2019). The number of patients aged 30-39 years increased from 3.9% in 2019 period to 5.8% in the pandemic (p = 0.009). Among the VTE risk factors, the rate of decreased activity increased significantly in the pandemic, and was much higher than that in 2019 (30.7% vs 22.6%, p < 0.0001). Under the risk of decreased activity, patients with comorbidities chronic diseases, especially diabetes, showed significantly a higher incidence of VTE (30.4% vs 22.0%, p < 0.0001). In the pandemic period, fewer patients were treated with anticoagulation alone (33.5% vs 36.7%, p = 0.05), and more underwent inferior vena cava filter (IVCF) implantation, compared with those in 2019 (66.5% vs 63.2%, p = 0.046). The pandemic increased the VTE risk of decreased activity among the non-COVID-19 population. Patients with comorbidities, especially diabetes, have a significant higher risk of VTE during the pandemic.


Subject(s)
Pandemics , Vena Cava Filters , Venous Thromboembolism , Adult , COVID-19 , Humans , Middle Aged , Retrospective Studies , Risk Factors , Venous Thromboembolism/epidemiology
6.
SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-4098

ABSTRACT

A review. Since Sept., 2019, COVID-19 spreads all over 26 countries, and more than 70 000 people got infected till Feb. 22th, 2020. COVID-19 has strong infectivity and can result in acute respiratory distress syndrome and multiple organ failure. These severe complications are believed to be the consequence of cytokine storm caused by the virus infection. In the "diagnosis and treatment of novel coronavirus pneumonia", glucocorticoid is recommended as the immunosuppressive agents to prevent acute immune reaction. But the usage of glucocorticoid may bring risks such as superinfection, prolonged course of disease or severe residual effects. Traditional Chinese Medicine might have advantages in the moderation of immune system. Actually, Traditional Chinese Medicine is now applied in the treatment of COVID-19 clin., and exhibits excellent therapeutic effects. In this review, the potential usage of Traditional Chinese drugs or Traditional prescriptions in inhibiting cytokine storm and acute lung injury are analyzed, which would be an effective strategy for the treatment of COVID-19.

8.
Chinese J. Lab. Med. ; 7(43): 687-690, 20200711.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-707369

ABSTRACT

Acute respiratory tract infections ranks first in China for various infectious diseases. Lower respiratory tract infections and related diseases caused a heavy burden on China's medical care and society. In particular, COVID has caused great losses. This article discusses the standardization of clinical pathological diagnosis of respiratory pathogen infection, in order to improve the correct diagnosis of the disease and facilitate the timely treatment of the disease.

9.
Curr Med Sci ; 40(4): 614-617, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-696956

ABSTRACT

The novel Coronavirus SARS-CoV-2 caused an outbreak of pneumonia in Wuhan, Hubei province of China in January 2020. This study aims to investigate the effects of different temperature and time durations of virus inactivation on the results of PCR testing for SARS-CoV-2. Twelve patients at the Renmin Hospital of Wuhan University suspected of being infected with SARS-CoV-2 were selected on February 13, 2020 and throat swabs were taken. The swabs were stored at room temperature (20-25°C), then divided into aliquots and subjected to different temperature for different periods in order to inactivate the viruses (56°C for 30, 45, 60 min; 65, 70, 80°C for 10, 15, 20 min). Control aliquots were stored at room temperature for 60 min. Then all aliquots were tested in a real-time fluorescence PCR using primers against SARS-CoV-2. Regardless of inactivation temperature and time, 7 of 12 cases (58.3%) tested were positive for SARS-CoV-2 by PCR, and cycle threshold values were similar. These results suggest that virus inactivation parameters exert minimal influence on PCR test results. Inactivation at 65°C for 10 min may be sufficient to ensure safe, reliable testing.


Subject(s)
Betacoronavirus/genetics , Betacoronavirus/isolation & purification , Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Coronavirus Infections/virology , Pneumonia, Viral/diagnosis , Pneumonia, Viral/virology , Real-Time Polymerase Chain Reaction/methods , Virus Inactivation , Adult , Aged , COVID-19 , COVID-19 Testing , China/epidemiology , Coronavirus Infections/epidemiology , Humans , Infection Control/methods , Medical Laboratory Personnel , Middle Aged , Molecular Diagnostic Techniques/methods , Occupational Exposure/prevention & control , Pandemics , Pneumonia, Viral/epidemiology , RNA, Viral/analysis , RNA, Viral/genetics , SARS-CoV-2 , Temperature , Time Factors
10.
Hypertension ; 76(3): 732-741, 2020 09.
Article in English | MEDLINE | ID: covidwho-641910

ABSTRACT

Hypertension is one of the most common comorbidities in patients with coronavirus disease 2019 (COVID-19). This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19. A total of 996 patients with COVID-19 were enrolled, including 282 patients with hypertension and 714 patients without hypertension. Propensity score-matched analysis (1:1 matching) was used to adjust the imbalanced baseline variables between the 2 groups. Patients with hypertension were further divided into the RAAS inhibitor group (n=41) and non-RAAS inhibitor group (n=241) according to their medication history. The results showed that COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8+ cells on admission. Patients with hypertension were more likely to have comorbidities and complications and were more likely to be classified as critically ill than those without hypertension. Cox regression analysis revealed that hypertension (hazard ratio, 95% CI, unmatched cohort [1.80, 1.20-2.70]; matched cohort [2.24, 1.36-3.70]) was independently associated with all-cause mortality in patients with COVID-19. In addition, hypertensive patients with a history of RAAS inhibitor treatment had lower levels of C-reactive protein and higher levels of CD4+ cells. The mortality of patients in the RAAS inhibitor group (9.8% versus 26.1%) was significantly lower than that of patients in the non-RAAS inhibitor group. In conclusion, hypertension may be an independent risk factor for all-cause mortality in patients with COVID-19. Patients who previously used RAAS inhibitors may have a better prognosis.


Subject(s)
Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors , Coronavirus Infections , Essential Hypertension , Pandemics , Pneumonia, Viral , Angiotensin Receptor Antagonists/administration & dosage , Angiotensin Receptor Antagonists/adverse effects , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Betacoronavirus , COVID-19 , China/epidemiology , Comorbidity , Coronavirus Infections/diagnosis , Coronavirus Infections/mortality , Coronavirus Infections/physiopathology , Essential Hypertension/diagnosis , Essential Hypertension/drug therapy , Essential Hypertension/epidemiology , Female , Hospital Mortality , Humans , Male , Middle Aged , Pneumonia, Viral/diagnosis , Pneumonia, Viral/mortality , Pneumonia, Viral/physiopathology , Prognosis , Renin-Angiotensin System/drug effects , Retrospective Studies , Risk Assessment , SARS-CoV-2
11.
Clin Chim Acta ; 510: 220-227, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-634044

ABSTRACT

Cases of coronavirus disease 2019 (COVID-19) have been breaking out around the world recently. However, the dynamic changes in the clinical symptoms and prognosis of COVID-19 patients remain unknown. According to the onset time of initial clinical symptoms, 843 COVID-19 patients admitted between Jan 22 and Feb 14, 2020 were divided into three groups: group A (Jan 21 to Jan 25, n = 324), group B (Jan 26 to Jan 31, n = 358) and group C (Feb 1 to Feb 10, n = 161). Data on the demographics, symptoms, first laboratory results, treatments and outcomes (within 12 days of hospitalization) were collected. The results showed that the median duration from symptom onset to admission shortened over time (13, 10 and 5 days, respectively, p < 0.05). Fewer patients had fever symptoms and bilateral pneumonia in group C than in the group A and B. Laboratory results showed that white blood cell, neutrophil, and platelet counts, lactic acid and D-dimer levels were lower, while lymphocyte, CD3, and CD8 counts were higher in group C. In addition, group C had more mild-moderate cases and fewer severe cases than the other two groups. More importantly, the incidence of complications (18.5%, 14.2% and 11.2%, respectively, p < 0.05) and all-cause mortality (11.7%, 8.4%, and 5.6%, respectively, p < 0.05) decreased over time. The clinical characteristics and prognosis of COVID-19 patients changed over time. Improved prognosis was found at a later stage.


Subject(s)
Coronavirus Infections/diagnosis , Hospitalization/trends , Pneumonia, Viral/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19 , China/epidemiology , Clinical Laboratory Techniques , Coronavirus Infections/complications , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/epidemiology , Female , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/epidemiology , Prognosis , Retrospective Studies , Time Factors , Tomography, X-Ray Computed , Young Adult
12.
Aging (Albany NY) ; 12(11): 10070-10086, 2020 06 04.
Article in English | MEDLINE | ID: covidwho-541306

ABSTRACT

BACKGROUND: Information about the clinical characteristics and mortality of patients with coronavirus disease 2019 at different ages is limited. RESULTS: The older group had more patients with dyspnea and fewer patients with fever and muscle pain. Older patients had more underlying diseases, secondary infection, myocardial injury, renal dysfunction, coagulation dysfunction, and immune dysfunction on admission. More older patients received immunoglobulin therapy and mechanical ventilation. The proportions of patients with multiple organ injuries, critically ill patients and death increased significantly with age. The older groups had higher cumulative death risk than the younger group. Hypertension, cerebrovascular disease, comorbidities, acute cardiac injury, shock and complications are independent predictors of death. CONCLUSIONS: The symptoms of the elderly patients were more atypical, with more comorbidities, secondary infection, organ injuries, immune dysfunction and a higher risk of critical illness. Older age was an important risk factor for mortality. METHODS: 1000 patients diagnosed with coronavirus disease 2019 from January 1, 2020 to February 14, 2020 were enrolled. According to age, patients were divided into group 1 (<60 years old), group 2 (60-74 years old) and group 3 (≥75 years old). The clinical symptoms, first laboratory results, CT findings, organ injuries, disease severity and mortality were analyzed.


Subject(s)
Coronavirus Infections/mortality , Pneumonia, Viral/mortality , Age Factors , Aged , Aged, 80 and over , COVID-19 , China/epidemiology , Coronavirus Infections/blood , Coronavirus Infections/complications , Coronavirus Infections/diagnostic imaging , Critical Illness , Female , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/complications , Pneumonia, Viral/diagnostic imaging , Prognosis , Retrospective Studies , Tomography, X-Ray Computed
13.
Chin. Trad. Herbal Drugs ; 6(51): 1375-1385, 20200328.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-380619

ABSTRACT

At the end of December, 2019, a novel coronavirus disease (COVID-19) outbreak was found in China. COVID-19 spreads all over 268 countries, and more than 70 000 people got infected till February 23th, 2020. COVID-19 can result in acute respiratory distress syndrome and multiple organ failure due to its strong infectivity and extensive spread. These severe complications are believed to be the consequence of cytokine storm caused by the virus infection. In the “Diagnosis and treatment of novel coronavirus pneumonia”, glucocorticoid is recommended as the immunosuppressive agents to prevent acute immune reaction in critical patients. However, the usage of glucocorticoid may bring severe residual effects such as superinfection risks, prolonged course of disease. Traditional Chinese medicine might have advantages in the moderation of immune system. Actually, TCM is now applied in the treatment of COVID-19 clinically, and exhibits excellent therapeutic effects. In this review, the potential usage of TCM or traditional prescriptions in inhibiting cytokine storm and treating in acute lung injury were analyzed, which would be an effective strategy for the treatment of COVID-19.

14.
Chin. Trad. Herbal Drugs ; 7(51): 1685-1693, 20200412.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-379968

ABSTRACT

Objective: To explore the effective chemical constituents of Jinhua Qinggan Granules for treatment of coronavirus disease 2019 (COVID-19). Methods: The compounds and action targets of eleven herbal medicines in Jinhua Qinggan Granules were collected via TCMSP. The genes corresponding to the targets were queried by the UniProt database, then the “herbal medicine-compound-target” network was established by Cytoscape software. The gene ontology (GO) function enrichment analysis and KEGG pathway enrichment analysis were performed by DAVID to predict their mechanism. Molecular docking was used to analyze the binding force of the core effective compounds in the “herbal medicine-compound-target” network with SARS-CoV-2 3CL hydrolase and angiotensin converting enzyme II (ACE2). Results: The “herbal medicine-compound-target” network contained 154 compounds and 276 targets, and the key targets involved PTGS2, HSP90AB1, HSP90AA1, PTGS1, NCOA2, etc. GO function enrichment analysis revealed 278 items, including ATP binding, transcription factor activation and regulation of apoptosis process, etc. KEGG pathway enrichment screened 127 signaling pathways, including TNF, PI3K/Akt and HIF-1 signaling pathways related to lung injury protection. The results of molecular docking showed that formononetin, stigmasterol, beta-sitosterol, anhydroicaritin and other key compounds have a certain degree of affinity with SARS-CoV-2 3CL hydrolase and ACE2. Conclusion: The effective compounds in Jinhua Qinggan Granules regulate multiple signaling pathways via binding ACE2 and acting on targets such as PTGS2, HSP90AB1, HSP90AA1, PTGS1, NCOA2 for the prevention of COVID-19.

15.
J Dig Dis ; 21(4): 199-204, 2020 Apr.
Article in English | MEDLINE | ID: covidwho-42091

ABSTRACT

An epidemic of an acute respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, now known as coronavirus disease 2019 (COVID-19), beginning in December 2019, has attracted an intense amount of attention worldwide. As the natural history and variety of clinical presentations of this disease unfolds, extrapulmonary symptoms of COVID-19 have emerged, especially in the digestive system. While the respiratory mode of transmission is well known and is probably the principal mode of transmission of this disease, a possibility of the fecal-oral route of transmission has also emerged in various case series and clinical scenarios. In this review article, we summarize four different aspects in published studies to date: (a) gastrointestinal manifestations of COVID-19; (b) microbiological and virological investigations; (c) the role of fecal-oral transmission; and (d) prevention and control of SARS-CoV-2 infection in the digestive endoscopy room. A timely understanding of the relationship between the disease and the digestive system and implementing effective preventive measures are of great importance for a favorable outcome of the disease and can help climnicians to mitigate further transmission by taking appropriate measures.


Subject(s)
Coronavirus Infections/transmission , Cross Infection/prevention & control , Digestive System Diseases , Endoscopy, Digestive System/standards , Gastroenterology/standards , Infection Control/standards , Pneumonia, Viral/transmission , Betacoronavirus/isolation & purification , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/virology , Cross Infection/etiology , Cross Infection/virology , Digestive System Diseases/diagnosis , Digestive System Diseases/etiology , Digestive System Diseases/microbiology , Digestive System Diseases/virology , Hospital Units/standards , Humans , Pandemics , Personal Protective Equipment/standards , Pneumonia, Viral/complications , Pneumonia, Viral/virology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL